10 Big Names With Effortless Double-Digit Gains

4. ImmunityBio Inc. (NASDAQ:IBRX)

ImmunityBio saw its share prices jump by 14.55 percent on Monday to finish at $6.93 apiece as investors loaded portfolios ahead of its participation in an event later this month by the American Society of Clinical Oncology (ASCO).

According to the company, it would participate in the three-day 2026 ASCO Genitourinary Cancers Symposium on February 26 and 28 at the Moscone West in San Francisco, California.

Held annually, the event focuses on the latest research and treatments for GU cancers, including prostate, bladder, kidney, and testicular cancer.

Meanwhile, investors will be watching out for developments about ImmunityBio Inc.’s (NASDAQ:IBRX) own cancer treatment, Anktiva.

Earlier this year, ImmunityBio Inc. (NASDAQ:IBRX) announced that it achieved a 700 percent sales jump from its therapy Anktiva, and that it would expand its operations into Saudi Arabia.

According to the company, it is set to begin selling Anktiva, in combination with an immune checkpoint inhibitor, for lung cancer patients in Saudi Arabia after securing the latter’s FDA approval.

Lung cancer is one of the most prevalent cancer types in Saudi.